RIGL · Rigel Pharmaceuticals Inc
$39.16
+0.66 (+1.71%)
At close · Jul 29
Market Cap
$712.33M
Shares
18.50M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$38.50
Open$37.48
Day$36.85–38.54
52W$19.51–52.24
Avg vol 30d389K
Short int3.2M · 17.1% float · 7.9d
Short vol71%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
+10%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
58%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+6%
trailing
YTD return
−10%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $35 › 200d $35 — 50d above 200d
Institutional flow
Distributing
26 of 149 funds reported for Jun 30 · net -64.2K sh shares · +10 new
Insider flow
Distributing
Net -$72.9K over 90 days · 100% sells
Short interest
Falling
17.07% of float · ▼ -2.9% MoM · 7.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
149 holders — mid 2-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
+64%
Y/Y
EPS growth
+1868%
Y/Y
Free cash flow
$75.2M
Valuation
P/E 2
below peers
Balance sheet
$11.9M
net debt
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Total revenues
· full year 2026
Maintained
$275M – $290M
prior FY $294.28M
midpoint −4.0% Y/Y
Net product sales
· full year 2026
Maintained
$255M – $265M
prior FY $294.28M
midpoint −11.6% Y/Y
Contract revenues
· full year 2026
Initiated
$20M – $25M
prior FY $294.28M
midpoint −92.4% Y/Y
Guided vs delivered
· last 1 settled
Total revenue
2025
guided $285M – $290M
$294.28M
Beat +2.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
58%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Golden cross
50d $35 › 200d $35 — 50d above 200d
Institutional flow
Distributing
26 of 149 funds reported for Jun 30 · net -64.2K sh shares · +10 new
Insider flow
Distributing
Net -$72.9K over 90 days · 100% sells
Short interest
Falling
17.07% of float · ▼ -2.9% MoM · 7.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
149 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $20
Now $39 · 58%
52-wk high $52
vs 200-day avg +11%
vs 50-day avg +10%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents, and short-term investments | $154.6M | as of December 31, 2025 | — |
| full-year net product sales growth | 60% | full year 2025 | — |
| RBC-TI (>=8 weeks) in evaluable transfusion dependent patients receiving R289 doses >=500 mg QD | 33% | Phase 1b dose escalation phase | — |
| RBC-TI in 500 mg BID dose group | 40% | Phase 1b dose escalation phase | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RIGL
this stock
Rigel Pharmaceuticals Inc
|
$712.33M | -10.1% | +64.1% | 2.0 | 17.1% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +8.8% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RIGL | -2.1% | -1.4% | +6.4% | -1.6% | -10.1% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -1.1% | -1.4% | -1.1% | -0.8% | -18.8% |
Key facts
CIK
1034842
CUSIP
766559702
13F (30d)
23 filings
23 filers
Visit website
Investor relations